The IPO pricing and demand will be the key near-term catalyst. Monitor for the final IPO price and first-day trading performance. Post-IPO, focus on Phase 3 bunionectomy and safety trial enrollment and topline data in H2 2027, which are the next major value inflection points for LTG-001.
Executive Summary
Latigo Biotherapeutics filed Amendment No. 2 to its S-1 registration statement for an IPO of 16,000,000 shares of common stock, with an expected price range of $16.00 to $18.00 per share. The company is a clinical-stage biopharmaceutical firm developing non-opioid Nav1.8 inhibitors for pain, with lead candidate LTG-001 showing positive Phase 2 abdominoplasty data. The IPO is critical to fund Phase 3 trials and address a going concern qualification, with net proceeds estimated at $247.2 million at the midpoint.
Key Financial Metrics
Key Facts
- Offering 16,000,000 shares at $16.00-$18.00 per share; 2,400,000 share greenshoe.
- Net proceeds estimated at ~$247.2M at $17.00 midpoint; funds runway into H2 2028.
- Lead candidate LTG-001 met primary endpoint in Phase 2 abdominoplasty trial (SPID48 62.1 pts vs placebo, p<0.001).
- Net losses of $61.2M (2024) and $109.2M (2025); accumulated deficit of $266.1M as of March 31, 2026.
- Going concern qualification from auditor; $42.2M cash as of March 31, 2026.
- Fast Track designation for LTG-001; Phase 3 bunionectomy and safety trials planned H2 2026.
- LTG-321 Phase 2 OA trial initiated; topline results expected H2 2027.
- Key investors: Westlake BioPartners, Foresite Capital, 5AM Ventures, Blue Owl Healthcare Opportunities.
Financial Impact
IPO expected to raise ~$247.2M net at midpoint, extending cash runway into H2 2028. Company has no revenue and cumulative losses of $266.1M.
Risk Factors
- Clinical failure: LTG-001 or LTG-321 may fail in Phase 3 or Phase 2 trials.
- Regulatory risk: FDA may require additional trials or not accept abdominoplasty as a pivotal trial.
- Financing risk: Despite IPO, substantial additional capital needed; may face dilutive future raises.
- Competition: Suzetrigine (Journavx) already approved; other Nav1.8 inhibitors in development.
- Going concern: Auditor expressed substantial doubt; IPO proceeds critical for survival.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-331205 |
| Document: d38775dex231.htm | 0001193125-26-331205 |
| Document: 0001193125-26-331205-index-headers.html | 0001193125-26-331205 |
| Document: 0001193125-26-331205-index.html | 0001193125-26-331205 |
| Document: 0001193125-26-331205.txt | 0001193125-26-331205 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $23.04 $23.73 | ▲ +2.99% | ▲ +3.54% | $15.21 (−33.98%) |
Aug 12, 2026 10w ago | 3 | $19.38 $20.06 | ▲ +3.54% | ▲ +2.84% | $15.21 (−21.50%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.21 (−17.87%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.21 (−17.87%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.21 (−17.87%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.21 (−17.87%) |
Aug 10, 2026 11w ago | 8-K | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.21 (−17.87%) |
Aug 7, 2026 11w ago | EFFECT | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.21 (−16.66%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.21 (−16.66%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.21 (−16.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers